- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04668833
ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter
Phase I Study of Autologous Lymphocyte Infusions After Radiation Therapy to Mitigate Radiation Induced Lymphopenia and Enhance Immune Reconstitution in Patients With Solid Tumor Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to determine the safety and preliminary efficacy of un-manipulated autologous lymphocyte infusion (ALI) using the patient's own lymphocytes collected using apheresis, and infused after the completion of radiation/chemoradiation. Primary Objective To investigate the preliminary efficacy of autologous lymphocyte infusion (ALI) in improving the absolute lymphocyte counts in lung and esophageal cancer patients who had undergone chemo-radiation (CRT). Secondary Objectives
- To evaluate the feasibility and safety of ALI in patients who had undergone chemoradiation.
- To identify lymphocyte clonal populations in the tissue that are specific for tumor cells
- To identify immune reconstitution in the peripheral blood shaped by ALI.
- To conduct clonal analysis using T-cell receptor (TCR) sequencing from tumor and from peripheral blood.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Gheath Al-Atrash
- Phone Number: 713-563-3324
- Email: galatras@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77090
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Histologically or cytologically documented NSCLC or esophageal cancers Stage II-IVA disease where definitive chemoradiation is the standard of care Age 18
Exclusion Criteria:
Prior radiotherapy to the chest Life expectancy<6 months Any systemic therapy, aside from standard of care immunotherapy, that is planned to be administered prior to 6 weeks after ALI. Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (Autologous Lymphocyte Infusions)
The purpose of this study is to determine the safety and preliminary efficacy of un-manipulated autologous lymphocyte infusion (ALI) using the patient's own lymphocytes collected using apheresis, and infused after the completion of radiation/chemoradiation.
|
On the day after completing the last dose of radiation therapy, the patient will have an appointment scheduled in the Apheresis Unit for the infusion of unmunipulated cryopreserved cells.
Patients will be pre medicated with acetaminophen (325-650 mg PO) and diphenhydramine (12.5-25 mg PO or IV) prior to infusion.
Cells will be infused without a leukoreduction filter at a rate determined by cell volume.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the absolute lymphocyte counts in lung and esophageal cancer patients who had undergone chemoradiation. (CRT)
Time Frame: Baseline to 6 weeks
|
The primary outcome is the change between the two measures, i.e., absolute lymphocyte counts at week 6 (+/- 14 days) minus baseline ALC, referred as ALC change.
Recently, we reviewed 755 patients with stage I-III esophageal carcinoma who received concurrent CRT with or without surgery in 2004-2015 [1].
The means of the absolute lymphocyte counts were 1,570 cells/µL (SD=610) and 980 cells/µL (SD=600) at based line and at the first follow-up visit post-CRT, respectively.
We incorporate this clinical evidence in our sample size justification.
|
Baseline to 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the feasibility of ALI in patients who had undergone chemoradiation.
Time Frame: Baseline to 6 weeks
|
The number of patients who fail to complete the planned ALI treatment (i.e., inability to collect cell dose or receive cell infusion), will be counted and used as the summary of feasibility for this study.
We will evaluate the feasibility of this study for future research and, it will be considered as feasible if less than 5 patients fail planned ALI treatment, while it will be stopped if 10 or more patients fail the planned ALI treatment during any time of the trial.
The primary outcome of ALC will be summarized by means and standard deviations along with box-and-whisker plots.
|
Baseline to 6 weeks
|
To evaluate the safety of ALI in patients who had undergone chemoradiation.
Time Frame: Baseline to 6 weeks
|
The method of Thall, Simon and Estey (1995) will be used for toxicity monitoring for this study. Denote the probability of toxicity by PT. We assume a priori, PT ~ beta (0.2, 1.8). We will stop the arm if Pr(PT> 0.1 | data)>0.80. That is, we will stop the arm for new patient enrollment if at any time during the study, we determine that there is more than 80% chance that the toxicity rate is more than 10%. This toxicity stopping rule will be applied starting from the 10th patient. |
Baseline to 6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gheath Al-Atrash, MD Anderson Cancer Center, Houston, Texas
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-1164
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor Malignancies
-
Synta Pharmaceuticals Corp.CompletedSolid Tumor MalignanciesUnited States
-
Weill Medical College of Cornell UniversityTerminatedSolid Tumor MalignanciesUnited States
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
Geron CorporationCompletedSolid Tumor MalignanciesUnited States
-
Novartis PharmaceuticalsTerminated
-
Eisai Inc.CompletedSolid Tumor Malignancies, CancerUnited States
-
New Mexico Cancer Care AllianceCompletedAdvanced Solid Tumor MalignanciesUnited States
-
Georgetown UniversityPfizerUnknownAdvanced Solid Tumor MalignanciesUnited States
-
OncoMed Pharmaceuticals, Inc.CompletedAdvanced Solid Tumor MalignanciesUnited States
Clinical Trials on Autologous lymphocyte infusion (ALI)
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)CompletedIntraocular Melanoma | Melanoma (Skin)United States
-
Assistance Publique - Hôpitaux de ParisPierre and Marie Curie University; Paris 12 Val de Marne UniversityCompletedHematological MalignancyFrance
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaboratorsCompletedHematopoietic Stem Cell Transplantation | Minimal Residual Disease | Relapse | Donor Lymphocyte InfusionChina
-
Masonic Cancer Center, University of MinnesotaCompletedAML | MDS | Leukemia, Lymphocytic, Acute | Leukemia, Myeloid, ChronicUnited States
-
Peking University People's HospitalUnknownAcute Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation | Minimal Residual Disease | Relapse | Donor Lymphocyte Infusion | Graft-versus-host DiseaseChina
-
Hospital Israelita Albert EinsteinRecruiting
-
Gangnam Severance HospitalRecruitingGastro-esophageal Junction Cancer | Relapsed or Advanced Gastric AdenocarcinomaKorea, Republic of
-
Hervor TherapeuticsCancer Institute and Hospital, Chinese Academy of Medical Sciences; Women's... and other collaboratorsRecruiting
-
Hong Kong Children's HospitalRecruitingHematopoietic Organs; DisorderHong Kong
-
Institut Paoli-CalmettesNot yet recruitingAcute Myeloid LeukemiaFrance